CL2013003091A1 - Compuestos derivados de 2-amino-3-(imidazol-2-il)-naftiridin(quinolin)-4-ona, inhibidores del receptor vegf r-3; procedimiento para prepararlos; medicamento; composicion farmaceutica; combinacion farmaceutica; y uso para tratar tumores solidos, linfomas, cancer de mama, artrosis, psoriasis, glaucoma e inflamacion, entre otros. - Google Patents

Compuestos derivados de 2-amino-3-(imidazol-2-il)-naftiridin(quinolin)-4-ona, inhibidores del receptor vegf r-3; procedimiento para prepararlos; medicamento; composicion farmaceutica; combinacion farmaceutica; y uso para tratar tumores solidos, linfomas, cancer de mama, artrosis, psoriasis, glaucoma e inflamacion, entre otros.

Info

Publication number: CL2013003091A1
Authority: CL; Chile
Prior art keywords: naphthyridin; quinolin; lymphomas; glaucoma; imidazol
Prior art date: 2011-05-20

Application number

CL2013003091A

Other languages

English (en)

Inventor

Alain Braun

Olivier Duclos

Gilbert Lasalle

Franz Lorge

Aurelie Strub

Valerie Martin

Olaf Ritzeler

Original Assignee

Sanofi Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-05-20

Filing date

2013-10-25

Publication date

2014-04-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44247865&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013003091(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-10-25 Application filed by Sanofi Sa filed Critical Sanofi Sa

2014-04-04 Publication of CL2013003091A1 publication Critical patent/CL2013003091A1/es

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Immunology (AREA)
Oncology (AREA)
Ophthalmology & Optometry (AREA)
Hematology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Communicable Diseases (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Dermatology (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CL2013003091A 2011-05-20 2013-10-25 Compuestos derivados de 2-amino-3-(imidazol-2-il)-naftiridin(quinolin)-4-ona, inhibidores del receptor vegf r-3; procedimiento para prepararlos; medicamento; composicion farmaceutica; combinacion farmaceutica; y uso para tratar tumores solidos, linfomas, cancer de mama, artrosis, psoriasis, glaucoma e inflamacion, entre otros. CL2013003091A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP11305624A EP2524915A1 (en)	2011-05-20	2011-05-20	2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors

Publications (1)

Publication Number	Publication Date
CL2013003091A1 true CL2013003091A1 (es)	2014-04-04

Family

ID=44247865

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2013003091A CL2013003091A1 (es)	2011-05-20	2013-10-25	Compuestos derivados de 2-amino-3-(imidazol-2-il)-naftiridin(quinolin)-4-ona, inhibidores del receptor vegf r-3; procedimiento para prepararlos; medicamento; composicion farmaceutica; combinacion farmaceutica; y uso para tratar tumores solidos, linfomas, cancer de mama, artrosis, psoriasis, glaucoma e inflamacion, entre otros.

Country Status (35)

Country	Link
US (2)	US9126972B2 (es)
EP (2)	EP2524915A1 (es)
JP (1)	JP5937201B2 (es)
KR (1)	KR102005121B1 (es)
CN (1)	CN103687852B (es)
AR (1)	AR086451A1 (es)
AU (1)	AU2012261077B2 (es)
BR (1)	BR112013029820B1 (es)
CA (1)	CA2833192C (es)
CL (1)	CL2013003091A1 (es)
CO (1)	CO6811857A2 (es)
CR (1)	CR20130541A (es)
CY (1)	CY1116720T1 (es)
DK (1)	DK2709996T3 (es)
DO (1)	DOP2013000241A (es)
EA (1)	EA023580B1 (es)
EC (1)	ECSP13013016A (es)
ES (1)	ES2548266T3 (es)
GT (1)	GT201300250A (es)
HR (1)	HRP20150974T1 (es)
HU (1)	HUE025111T2 (es)
IL (1)	IL229210A0 (es)
MA (1)	MA35196B1 (es)
MX (1)	MX348842B (es)
NI (1)	NI201300125A (es)
PE (1)	PE20141527A1 (es)
PL (1)	PL2709996T3 (es)
PT (1)	PT2709996E (es)
SG (1)	SG194204A1 (es)
SI (1)	SI2709996T1 (es)
TN (1)	TN2013000420A1 (es)
TW (1)	TWI532740B (es)
UA (1)	UA109942C2 (es)
UY (1)	UY34082A (es)
WO (1)	WO2012159959A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2952934B1 (fr) *	2009-11-23	2012-06-22	Sanofi Aventis	Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
EP2524915A1 (en)	2011-05-20	2012-11-21	Sanofi	2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors
EP2874625B1 (en) *	2012-07-17	2017-05-17	Sanofi	Use of vegfr-3 inhibitors for treating hepatocellular carcinoma
JOP20190086A1 (ar)	2016-10-21	2019-04-18	Novartis Ag	مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
WO2019149782A1 (en) *	2018-01-31	2019-08-08	Sanofi	Modified lipidated relaxin b chain peptides and their therapeutic use
HU231285B1 (hu)	2018-04-18	2022-08-28	Printnet Kereskedelmi És Szolgáltató Kft.	A miozin-2-izoformákat szelektíven gátló, gyógyászatilag hatásos vegyületek

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5919970A (en)	1997-04-24	1999-07-06	Allergan Sales, Inc.	Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US7615565B2 (en)	2002-07-31	2009-11-10	Bayer Schering Pharma Aktiengesellschaft	VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
CN1191252C (zh) *	2003-08-11	2005-03-02	中国药科大学	3－位取代的喹诺酮衍生物及其在药学上的应用
AU2004288709B2 (en) *	2003-11-07	2011-01-06	Novartis Vaccines And Diagnostics, Inc.	Methods for synthesizing quinolinone compounds
KR100744826B1 (ko) *	2006-04-05	2007-08-01	한국화학연구원	이미다졸기가 치환된 퀴놀리논 유도체
JP2010522765A (ja)	2007-03-28	2010-07-08	アレイバイオファーマ、インコーポレイテッド	受容体チロシンキナーゼとしてのイミダゾ［１，２−ａ］ピリジン化合物
FR2917412B1 (fr)	2007-06-13	2009-08-21	Sanofi Aventis Sa	Derives de 7-alkynyl, 1,8-naphthyridones, leur preparation et leur application en therapeutique
WO2009053799A1 (en) *	2007-10-24	2009-04-30	Glenmark Pharmaceuticals, S.A.	Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
FR2933700B1 (fr)	2008-07-08	2010-07-30	Sanofi Aventis	Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
WO2010073078A2 (en) *	2008-12-22	2010-07-01	Orchid Research Laboratories Ltd.	Heterocyclic compounds as hdac inhibitors
FR2952934B1 (fr)	2009-11-23	2012-06-22	Sanofi Aventis	Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
EP2524915A1 (en)	2011-05-20	2012-11-21	Sanofi	2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors
EP2874625B1 (en) *	2012-07-17	2017-05-17	Sanofi	Use of vegfr-3 inhibitors for treating hepatocellular carcinoma

2011
- 2011-05-20 EP EP11305624A patent/EP2524915A1/en not_active Withdrawn
2012
- 2012-05-16 CN CN201280035801.0A patent/CN103687852B/zh active Active
- 2012-05-16 PL PL12722347T patent/PL2709996T3/pl unknown
- 2012-05-16 UA UAA201314927A patent/UA109942C2/ru unknown
- 2012-05-16 EA EA201391744A patent/EA023580B1/ru not_active IP Right Cessation
- 2012-05-16 CA CA2833192A patent/CA2833192C/en active Active
- 2012-05-16 HU HUE12722347A patent/HUE025111T2/en unknown
- 2012-05-16 EP EP12722347.7A patent/EP2709996B1/en active Active
- 2012-05-16 SI SI201230305T patent/SI2709996T1/sl unknown
- 2012-05-16 BR BR112013029820A patent/BR112013029820B1/pt active IP Right Grant
- 2012-05-16 SG SG2013077185A patent/SG194204A1/en unknown
- 2012-05-16 PT PT127223477T patent/PT2709996E/pt unknown
- 2012-05-16 US US14/117,750 patent/US9126972B2/en active Active
- 2012-05-16 DK DK12722347.7T patent/DK2709996T3/en active
- 2012-05-16 MX MX2013013572A patent/MX348842B/es active IP Right Grant
- 2012-05-16 ES ES12722347.7T patent/ES2548266T3/es active Active
- 2012-05-16 AU AU2012261077A patent/AU2012261077B2/en active Active
- 2012-05-16 WO PCT/EP2012/059145 patent/WO2012159959A1/en active Application Filing
- 2012-05-16 KR KR1020137030330A patent/KR102005121B1/ko active IP Right Grant
- 2012-05-16 JP JP2014510800A patent/JP5937201B2/ja active Active
- 2012-05-16 PE PE2013002448A patent/PE20141527A1/es not_active Application Discontinuation
- 2012-05-18 AR ARP120101766A patent/AR086451A1/es active IP Right Grant
- 2012-05-18 TW TW101117880A patent/TWI532740B/zh active
- 2012-05-18 UY UY0001034082A patent/UY34082A/es not_active Application Discontinuation
2013
- 2013-10-14 TN TNP2013000420A patent/TN2013000420A1/fr unknown
- 2013-10-15 DO DO2013000241A patent/DOP2013000241A/es unknown
- 2013-10-16 GT GT201300250A patent/GT201300250A/es unknown
- 2013-10-22 CR CR20130541A patent/CR20130541A/es unknown
- 2013-10-25 CL CL2013003091A patent/CL2013003091A1/es unknown
- 2013-11-03 IL IL229210A patent/IL229210A0/en active IP Right Grant
- 2013-11-08 EC ECSP13013016 patent/ECSP13013016A/es unknown
- 2013-11-19 NI NI201300125A patent/NI201300125A/es unknown
- 2013-11-20 CO CO13273134A patent/CO6811857A2/es active IP Right Grant
- 2013-12-18 MA MA36590A patent/MA35196B1/fr unknown
2015
- 2015-07-24 US US14/809,087 patent/US9675606B2/en active Active
- 2015-09-16 HR HRP20150974TT patent/HRP20150974T1/hr unknown
- 2015-09-24 CY CY20151100842T patent/CY1116720T1/el unknown

Also Published As

Publication number	Publication date
PL2709996T3 (pl)	2015-12-31
CN103687852A (zh)	2014-03-26
US20140094488A1 (en)	2014-04-03
EA201391744A1 (ru)	2014-03-31
JP2014513707A (ja)	2014-06-05
EA023580B1 (ru)	2016-06-30
AU2012261077B2 (en)	2016-05-05
CA2833192C (en)	2019-10-22
EP2709996A1 (en)	2014-03-26
PE20141527A1 (es)	2014-11-08
EP2709996B1 (en)	2015-06-24
CY1116720T1 (el)	2017-03-15
TW201300386A (zh)	2013-01-01
BR112013029820B1 (pt)	2020-02-04
HUE025111T2 (en)	2016-02-29
KR20140025465A (ko)	2014-03-04
AU2012261077A1 (en)	2013-12-12
UA109942C2 (ru)	2015-10-26
US9675606B2 (en)	2017-06-13
ECSP13013016A (es)	2013-12-31
PT2709996E (pt)	2015-10-16
CA2833192A1 (en)	2012-11-29
CR20130541A (es)	2013-12-09
NZ617931A (en)	2015-05-29
HRP20150974T1 (en)	2015-10-09
JP5937201B2 (ja)	2016-06-22
AR086451A1 (es)	2013-12-11
BR112013029820A2 (pt)	2016-12-06
MX348842B (es)	2017-06-30
SI2709996T1 (sl)	2015-10-30
KR102005121B1 (ko)	2019-07-29
WO2012159959A1 (en)	2012-11-29
MX2013013572A (es)	2014-01-16
ES2548266T3 (es)	2015-10-15
MA35196B1 (fr)	2014-06-02
NI201300125A (es)	2014-02-20
US20150328205A1 (en)	2015-11-19
DK2709996T3 (en)	2015-09-28
TWI532740B (zh)	2016-05-11
EP2524915A1 (en)	2012-11-21
IL229210A0 (en)	2014-01-30
SG194204A1 (en)	2013-12-30
DOP2013000241A (es)	2013-12-31
US9126972B2 (en)	2015-09-08
CN103687852B (zh)	2016-08-17
CO6811857A2 (es)	2013-12-16
TN2013000420A1 (en)	2015-03-30
GT201300250A (es)	2015-03-05
UY34082A (es)	2013-01-03

Publication	Publication Date	Title
CL2013003091A1 (es)	2014-04-04	Compuestos derivados de 2-amino-3-(imidazol-2-il)-naftiridin(quinolin)-4-ona, inhibidores del receptor vegf r-3; procedimiento para prepararlos; medicamento; composicion farmaceutica; combinacion farmaceutica; y uso para tratar tumores solidos, linfomas, cancer de mama, artrosis, psoriasis, glaucoma e inflamacion, entre otros.
IL268974B (en)	2020-08-31	Labeled inhibitors of prostate-specific membrane antigen (psma), their use as imaging agents and as pharmaceutical agents for the treatment of prostate cancer
CL2016000922A1 (es)	2017-01-27	Derivados de anillo bicíclico fusionado piridilo como inhibidores fgfr4
CL2014003227A1 (es)	2015-02-06	Compuestos derivados de imidazol condensados, como moduladores de la actividad del receptor del factor de crecimiento epidermico (egfr); composicion y combinacion farmaceutica que los comprende; y su uso para el tratamiento de cancer colorrectal, de mama, de pancreas, de ovario, entre otros.
IL238662A (en)	2017-08-31	Bandostatin derivatives, containing them and used to treat cancer
CL2015003280A1 (es)	2016-06-24	Derivados de benzimidazol como inhibidores de bromodominio
CL2015001785A1 (es)	2015-10-02	Compuestos derivados de heterociclos nitrogenados, moduladores de quinasas; metodo de preparacion; compuesto iintermediario; composicion farmaceutica; y un metodo para tratar un sujeto que posee una enferemedad o condicion como cancer, aml, tumores estromales gastrointestinales o mastocitosis.
CL2014000225A1 (es)	2014-12-05	Compuestos derivados de 1,2,4-triazol; composicion farmaceutica; procedimiento de preparacion de procursores de los mismos y el uso como moduladores del transporte nuclear en el tratamiento de enfermedades tales como cancer.
CL2015000337A1 (es)	2015-05-04	Compuestos derivados de 2,3-benzodiazepinas sustituidas; compuestos intermediarios; formulacion farmaceutica; uso para la profilaxis y/o terapia de trastornos tumorales tales como leucemias, carcinoma de prostata, carcinoma de mama, melanomas, entre otros y control de fertilidad masculina.
MX2016002974A (es)	2016-06-02	Eteres de arilo y sus usos.
UY35663A (es)	2015-02-27	Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
CL2014002873A1 (es)	2015-04-24	Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
CO6511228A2 (es)	2012-08-31	(heteroarilmetil)tiohidantoínas sustituidas como drogas anticáncer
ECSP14017586A (es)	2015-09-30	Derivados de tetrahidro-quinazolinona
MX368844B (es)	2019-10-16	Derivados de imidazolina, métodos de preparación de los mismos, y sus aplicaciones en medicina.
CU24167B1 (es)	2016-03-31	Derivados de triazolopirazinas sustituidas como inhibidores del receptor c-met o hgf para tratar el cáncer
CL2014001853A1 (es)	2015-06-26	Compuestos derivados de pirrol sustituido; procedimiento de preparacion; composicion farmaceutica que los contiene; combinacion farmaceutica; uso para tratar enfermedades tales como canceres y enfermedades del sistema inmunitario.
CL2013003686A1 (es)	2014-08-29	Compuestos derivados de ergolina, antagonista del receptor de 5-ht1d; útiles para el tratamiento de la migraña.
PA8796001A1 (es)	2009-04-23	Moduladores tieno- y furo-pirimidina del receptor de histamina h4
PT4095130T (pt)	2024-04-04	Inibidores marcados do antígeno de membrana específico da próstata (psma), seu uso como agentes de imagem e agentes farmacêuticos para o tratamento do cancro da próstata
GT201500243A (es)	2015-11-18	Moduladores benzoimidazol-2-il pirimidinas del receptor h4 de histamina
BR112016011734A2 (pt)	2017-08-08	Indóis substituídos e funcionalizados como agentes anti-câncer
CL2012001322A1 (es)	2012-08-17	Compuestos derivados de piridinopiridinona, inhibidores pdgf; procedimiento de preparacion de estos; composición farmacéutica que los comprende; combinación farmacéutica; y su uso en el tratamiento del cancer, ateroesclerosis, enfermedades cardiacas, diabetes, renales, entre otras.
CL2015001318A1 (es)	2015-10-02	Compuestos derivados de pirazina, agonistas del receptor cb2; proceso de obtencion; composicion farmaceutica y el uso en el tratamiento de enfermedades tales como aterosclerosis, glaucoma, diabetes, entre otras.
AP2015008714A0 (en)	2015-09-30	Pharmaceutical composition comprising albumin-binding arginine deiminase for cancer targeting treatment